Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy.
Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 25 | 8.22 Decreased by -13.93% | 8.48 Decreased by -3.03% |
| Jan 31, 25 | 12.07 Increased by +1.77% | 11.38 Increased by +6.06% |
| Oct 31, 24 | 12.46 Increased by +7.51% | 11.69 Increased by +6.59% |
| Aug 1, 24 | 11.56 Increased by +12.89% | 10.61 Increased by +8.95% |
| May 2, 24 | 9.55 Decreased by -5.35% | 10.09 Decreased by -5.35% |
| Feb 2, 24 | 11.86 Decreased by -5.57% | 10.73 Increased by +10.53% |
| Nov 2, 23 | 11.59 Increased by +4.04% | 10.72 Increased by +8.12% |
| Aug 3, 23 | 10.24 Increased by +4.81% | 9.84 Increased by +4.07% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 3.03 B Decreased by -3.70% | 808.70 M Increased by +12.01% | Increased by +26.70% Increased by +16.31% |
| Dec 31, 24 | 3.79 B Increased by +10.33% | 917.70 M Decreased by -20.86% | Increased by +24.22% Decreased by -28.27% |
| Sep 30, 24 | 3.72 B Increased by +10.65% | 1.34 B Increased by +33.02% | Increased by +36.03% Increased by +20.22% |
| Jun 30, 24 | 3.55 B Increased by +12.32% | 1.43 B Increased by +47.90% | Increased by +40.38% Increased by +31.68% |
| Mar 31, 24 | 3.15 B Decreased by -0.54% | 722.00 M Decreased by -11.71% | Increased by +22.96% Decreased by -11.23% |
| Dec 31, 23 | 3.43 B Increased by +0.58% | 1.16 B Decreased by -3.13% | Increased by +33.77% Decreased by -3.69% |
| Sep 30, 23 | 3.36 B Increased by +14.53% | 1.01 B Decreased by -23.40% | Increased by +29.97% Decreased by -33.12% |
| Jun 30, 23 | 3.16 B Increased by +10.53% | 968.40 M Increased by +13.65% | Increased by +30.66% Increased by +2.82% |